AP1030

AP1030 is an orally administered small molecule drug candidate developed by Action Pharma for the treatment of type 2 diabetes associated with obesity. It acts as a dual positive allosteric modulator (PAM) of the melanocortin 4 receptor (MC4R) and the melanocortin 1 receptor (MC1R). Activation of MC4R in the central nervous system helps regulate appetite and glucose metabolism, while activation of MC1R exerts anti-inflammatory effects that reduce low-grade inflammation in adipose tissue and improve peripheral insulin resistance. Unlike earlier orthosteric MC4R agonists, AP1030 has demonstrated a favorable safety profile in Phase IB clinical trials, specifically showing no significant impact on blood pressure while effectively influencing glucose metabolism.